Figure 2.

Difference in SVR12 rates between black and non-black subjects by subgroups for those with HCV GT1 alone in 12-week regimens. *: Including non-cirrhotic subjects and subjects with missing cirrhosis status; **: including GT1b subjects and subjects with other or undetermined subtype; ***: excluding subjects with missing IL-28B status. BMI: body mass index; CI: confidence interval; HCV: hepatitis C virus; SVR12: sustained virological response assessed 12 weeks following cessation of treatment; TE: treatment experienced; TN: treatment naive